Please login to the form below

Not currently logged in

Amgen invests $200m in Singapore monoclonal antibody facility

New manufacturing plant will produce both clinical and commercial products

Amgen flag 

Amgen is to invest around $200m in a new Singapore facility to manufacture both clinical and commercial products with an initial focus on monoclonal antibodies.

The new plant will be based in the Tuas Biomedical Park area of Singapore and construction is expected to begin in the next few months.

Madhu Balachandran, executive VP of operations, said: "Amgen is pleased to be planning for a new world-class facility in Singapore as part of our global expansion strategy.

“Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment.”

The site will be staffed with both new recruits and experienced staff and Amgen is partnering with local universities to recruit for a number of manufacturing and quality positions.

The move will expand Amgen's existing Asian footprint, which currently consists of bases in Mumbai, Hong Kong and Tokyo, and bring the US biotech firm local experience in a market it is keen to break into.

At the end of last year, Amgen highlighted Singapore, along with countries such as China, South Korea and the Philippines, as locations it was looking to open new clinical sites.

The company's manufacturing investment is the second announcement in recent months of industry interest in Singapore and follows Novartis' November decision to revive its delayed biotech plans for the city-state.

The Swiss pharma company will begin work on its $500m biotechnology facility later this year and hopes to have the production plant up and running by the end of 2016.

17th January 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...